Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (Diluted Average) (2018 - 2025)

Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 10 years, with the latest figure at $161.0 million for Q1 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 2.08% to $161.0 million in Q1 2025 year-over-year; TTM through Mar 2025 was $161.0 million, a 2.08% increase, with the full-year FY2020 number at $160.7 million, up 2.97% from a year prior.
  • Shares Outstanding (Diluted Average) hit $161.0 million in Q1 2025 for Ironwood Pharmaceuticals, up from $158.4 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for IRWD hit a ceiling of $161.0 million in Q1 2025 and a floor of $155.4 million in Q2 2023.
  • Historically, Shares Outstanding (Diluted Average) has averaged $158.1 million across 3 years, with a median of $158.0 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): grew 1.92% in 2024 and later grew 2.08% in 2025.
  • Tracing IRWD's Shares Outstanding (Diluted Average) over 3 years: stood at $155.4 million in 2023, then grew by 1.92% to $158.4 million in 2024, then grew by 1.65% to $161.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for IRWD at $161.0 million in Q1 2025, $158.4 million in Q2 2024, and $157.7 million in Q1 2024.